Table 3.

Summary of cost variables in the cost-effectiveness modelling analysis

Item	Mean cost (USD)	Reference
Oncotype DX test	5141	Genomic Health Ltd. Turkey branch
Endocrine therapy (years 1–5)	256.5	Turkish Cost-Effectiveness Analysis of Screening in Breast Cancer
Endocrine therapy (years 6–8)	289.6	Turkish Cost-Effectiveness Analysis of Screening in Breast Cancer
Chemotherapy	1436	Turkish Oncotype-Dx Decision Impact Study
Distant recurrence (monthly)	98.08	Turkish Oncotype-Dx Decision Impact Study and Turkish Cost-Effectiveness Analysis of Screening in Breast Cancer
Chemotherapy adverse events	468.5	Turkish Oncotype-Dx Decision Impact Study